NeoPharm commences enrollment in Phase II clinical trial of LE-DT for pancreatic cancer

NeoPharm, Inc. (Other OTC: NEOL.PK), announced today that it has started enrolling patients in its Phase II clinical trial for liposome entrapped docetaxel (LE-DT), as a frontline treatment of pancreatic cancer patients with locally advanced or metastatic disease. LE-DT is a novel, proprietary liposomal delivery system of docetaxel, the active ingredient of Taxotere^®.

“Unfortunately, pancreatic cancer is one of the cancers which has no effective treatment. We are hoping that this new modality of treatment with LE-DT will bring some hope and treatment options to those unfortunate patients”

"Unfortunately, pancreatic cancer is one of the cancers which has no effective treatment. We are hoping that this new modality of treatment with LE-DT will bring some hope and treatment options to those unfortunate patients" commented Dr. Aquilur Rahman, President and Chief Executive Officer of NeoPharm.

"Following the very impressive results of the LE-DT Phase I trial, this open-label, Phase II study will help us determine the antitumor effect of LE-DT in this lethal disease. Progression Free Survival and Overall Survival along with a number of biologic markers such as CA-19-9 and SPARC expression, which are potentially related to the response of the disease, will be monitored. In addition, we will be evaluating the quality of life in these patients with metastatic disease."

Patients enrolled in the study will receive 110mg/m² of LE-DT administered intravenously over 60 minutes every three weeks. NeoPharm anticipates enrolling a total of 40 patients in this initial Phase II trial at three-to-four cancer centers in the US.